et the question remains on tips on how to predict these complications. It’s relevant to consider prophylactic measures for avoiding hypercoagulability. Progressive diffuse abdominal pain with no substantial alterations on coagulation profile or other threat factors should raise the awareness for mesenteric thrombosis. Actually, few circumstances of intestinal thrombosis exist inside the literature thinking of our patient certainly one of the initial circumstances of subacute mesenteric venous thrombosis within a non-severe COVID-19 patient. More case reports and descriptive data are necessary within the literature to enhance the index of suspicion for these kinds of complications.studies concluding that there is no distinction in collateral formation, recanalization and mortality, regardless of whether anticoagulation had been prescribed or not. These findings emphasize the predominant part of inflammation, rising uncertainty of risk/benefit ratio of anticoagulation. When portal and superior mesenteric veins are affected, anticoagulation seems a affordable attitude, considering the danger of hepatic decompensation and bowel ischemia. Far more studies are needed to consolidate this proof and to establish well-defined recommendations in other circumstances (e.g., isolated thrombosis of splenic vein, as in this case).V T E D I AG N O S I S PB1175|Detection of Appropriate Ventricular Dysfunction in Acute Pulmonary Embolism by CT Scan: A Systematic Critique and Metaanalysis N. Chornenki1; K. Poorzargar2; M. Shanjer2; L. Mbuagbaw2;PB1174|Does Anticoagulation Impact Outcome of Splenic Vein Thrombosis in Acute pancreatitis L. Vieira; S. Lopes; R. Pombal; R. Neto; A. Magalh s; M. Figueiredo Immunohemotherapy Service, Vila Nova de Gaia/Espinho Hospital Centre, Vila Nova de Gaia, Portugal Background: Splanchnic venous thrombosis (SVT) is usually a wellestablished complication of acute pancreatitis (AP) and may influence splenic, portal and superior mesenteric veins, either isolated or in combination. Its pathogenesis is closely associated to inflammation, top to cellular infiltration, formation of pancreatic/peripancreatic collections that contribute to venous stasis and systemic activation of haemostasis. Aims: Description of a case of SVT AP-associated. Methods: Collection of clinical data in SCl ico application. Outcomes: A 47-year-old female patient, with antecedents of prior AP secondary to hypertriglyceridemia, was admitted to emergency division with discomfort in upper quadrants of abdomen, radiating towards the back, with nausea and vomiting, over the past couple of hours. By means of clinical, analytical and imaging evaluation, the diagnosis of AP secondary to hypertriglyceridemia was established. The patient was hospitalized and, 4 days later, as a consequence of clinical worsening, a computed tomography (CT) was performed, revealing splenic vein thrombosis and pancreatic necrosis. Enoxaparin in therapeutic dose was Cathepsin B Inhibitor MedChemExpress initiated. The patient remained hospitalized for 18 days and enoxaparin was replaced by rivaroxaban 20mg as soon as everyday at discharge. Three months later, CT showed persistence of thrombosis, with perigastric/perisplenic collateral circulation. Caspase 2 Inhibitor Molecular Weight Contemplating this substantial collateral circulation, comprehensive recanalization was no longer anticipated. Anticoagulation was maintained for a total period of 6 months. Conclusions: Management of thrombosis in AP remains challenging. There’s no consensus on anticoagulation in this setting, with someM. Crowther2; A. Delluc3; D. SiegalQueens University, Kingston, Canada; 2McMaster University,Hamilton, Cana